Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke: A Randomized Clinical Trial
- PMID: 26716735
- DOI: 10.1001/jamaneurol.2015.3886
Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke: A Randomized Clinical Trial
Erratum in
-
Affiliation Error in Group Information Listing.JAMA Neurol. 2016 Apr;73(4):481. doi: 10.1001/jamaneurol.2016.0104. JAMA Neurol. 2016. PMID: 26858086 No abstract available.
Abstract
Importance: Intra-arterial treatment (IAT) for acute ischemic stroke caused by intracranial arterial occlusion leads to improved functional outcome in patients treated within 6 hours after onset. The influence of treatment delay on treatment effect is not yet known.
Objective: To evaluate the influence of time from stroke onset to the start of treatment and from stroke onset to reperfusion on the effect of IAT.
Design, setting, and participants: The Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) was a multicenter, randomized clinical open-label trial of IAT vs no IAT in 500 patients. The time to the start of treatment was defined as the time from onset of symptoms to groin puncture (TOG). The time from onset of treatment to reperfusion (TOR) was defined as the time to reopening the vessel occlusion or the end of the procedure in cases for which reperfusion was not achieved. Data were collected from December 3, 2010, to June 3, 2014, and analyzed (intention to treat) from July 1, 2014, to September 19, 2015.
Main outcomes and measures: Main outcome was the modified Rankin Scale (mRS) score for functional outcome (range, 0 [no symptoms] to 6 [death]). Multiple ordinal logistic regression analysis estimated the effect of treatment and tested for the interaction of time to randomization, TOG, and TOR with treatment. The effect of treatment as a risk difference on reaching independence (mRS score, 0-2) was computed as a function of TOG and TOR. Calculations were adjusted for age, National Institutes of Health Stroke Scale score, previous stroke, atrial fibrillation, diabetes mellitus, and intracranial arterial terminus occlusion.
Results: Among 500 patients (58% male; median age, 67 years), the median TOG was 260 (interquartile range [IQR], 210-311) minutes; median TOR, 340 (IQR, 274-395) minutes. An interaction between TOR and treatment (P = .04) existed, but not between TOG and treatment (P = .26). The adjusted risk difference (95% CI) was 25.9% (8.3%-44.4%) when reperfusion was reached at 3 hours, 18.8% (6.6%-32.6%) at 4 hours, and 6.7% (0.4%-14.5%) at 6 hours.
Conclusion and relevance: For every hour of reperfusion delay, the initially large benefit of IAT decreases; the absolute risk difference for a good outcome is reduced by 6% per hour of delay. Patients with acute ischemic stroke require immediate diagnostic workup and IAT in case of intracranial arterial vessel occlusion.
Trial registration: trialregister.nl Identifier: NTR1804.
Similar articles
-
Baseline Blood Pressure Effect on the Benefit and Safety of Intra-Arterial Treatment in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands).Stroke. 2017 Jul;48(7):1869-1876. doi: 10.1161/STROKEAHA.116.016225. Epub 2017 Apr 21. Stroke. 2017. PMID: 28432266 Clinical Trial.
-
Comparison of final infarct volumes in patients who received endovascular therapy or intravenous thrombolysis for acute intracranial large-vessel occlusions.JAMA Neurol. 2013 Jul;70(7):831-6. doi: 10.1001/jamaneurol.2013.413. JAMA Neurol. 2013. PMID: 23699864
-
Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.Int J Stroke. 2015 Apr;10(3):439-48. doi: 10.1111/ijs.12459. Int J Stroke. 2015. PMID: 25777831 Free PMC article. Clinical Trial.
-
Is bridging with intravenous thrombolysis of any benefit in endovascular therapy for acute ischemic stroke?World Neurosurg. 2014 Sep-Oct;82(3-4):e453-8. doi: 10.1016/j.wneu.2013.01.097. Epub 2013 Feb 1. World Neurosurg. 2014. PMID: 23376392 Review.
-
Endovascular treatment or general treatment: how should acute ischemic stroke patients choose to benefit from them the most?: A systematic review and meta-analysis.Medicine (Baltimore). 2020 May;99(20):e20187. doi: 10.1097/MD.0000000000020187. Medicine (Baltimore). 2020. PMID: 32443338 Free PMC article.
Cited by
-
A Review on Adjunctive Therapies for Endovascular Treatment in Acute Ischemic Stroke.J Neuroendovasc Ther. 2023;17(11):263-271. doi: 10.5797/jnet.ra.2023-0035. Epub 2023 Jul 12. J Neuroendovasc Ther. 2023. PMID: 38025256 Free PMC article. Review.
-
One-stop stroke management platform reduces workflow times in patients receiving mechanical thrombectomy.Front Neurol. 2023 Jan 18;13:1044347. doi: 10.3389/fneur.2022.1044347. eCollection 2022. Front Neurol. 2023. PMID: 36742054 Free PMC article.
-
Disability Adjusted Life Years due to Ischaemic Stroke Preventable by Real-Time Stroke Detection-A Cost-Utility Analysis of Hypothetical Stroke Detection Devices.Front Neurol. 2018 Oct 1;9:814. doi: 10.3389/fneur.2018.00814. eCollection 2018. Front Neurol. 2018. PMID: 30327638 Free PMC article.
-
Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials.BMJ. 2017 May 3;357:j1710. doi: 10.1136/bmj.j1710. BMJ. 2017. PMID: 28468840 Free PMC article. Clinical Trial.
-
Mechanical Thrombectomy with the Embolus Retriever with Interlinked Cages in Acute Ischemic Stroke: ERIC, the New Boy in the Class.AJNR Am J Neuroradiol. 2017 Jul;38(7):1356-1361. doi: 10.3174/ajnr.A5201. Epub 2017 May 11. AJNR Am J Neuroradiol. 2017. PMID: 28495947 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical